Sambrik Medisciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 18-07-2024
- Paid Up Capital ₹ 0.10 M
as on 18-07-2024
- Company Age 7 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.97 M
as on 18-07-2024
- Revenue 28.18%
(FY 2023)
- Profit 1.47%
(FY 2023)
- Ebitda 88.76%
(FY 2023)
- Net Worth 26.02%
(FY 2023)
- Total Assets 20.54%
(FY 2023)
About Sambrik Medisciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.97 M.
Kamlesh Shah, Sandip Mahamuni, Brijesh Kulkarni, and Two other members serve as directors at the Company.
- CIN/LLPIN
U74999PN2017PTC170127
- Company No.
170127
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Apr 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Sambrik Medisciences?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sandeep Valsangkar  | Director | 26-Apr-2017 | Current |
| Brijesh Kulkarni | Director | 26-Apr-2017 | Current |
| Kamlesh Shah | Director | 26-Apr-2017 | Current |
| Sandip Mahamuni | Director | 26-Apr-2017 | Current |
| Madhav Khonde | Director | 26-Apr-2017 | Current |
Financial Performance of Sambrik Medisciences.
Sambrik Medisciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 28.18% increase. The company also saw a slight improvement in profitability, with a 1.47% increase in profit. The company's net worth Soared by an impressive increase of 26.02%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sambrik Medisciences?
In 2023, Sambrik Medisciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Bask-Ray India Private LimitedActive 8 months 5 daysSandip Mahamuni, Brijesh Kulkarni and 2 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 17 Jan 2023 | ₹1.97 M | Open |
How Many Employees Work at Sambrik Medisciences?
Sambrik Medisciences has a workforce of 24 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sambrik Medisciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sambrik Medisciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
